Overactive bladder – 18 years – part I
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | International Braz J Urol (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188 |
Resumo: | ABSTRACT Abstract: Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. |
id |
SBU-1_f3c818cfdcc47c3d025ef25892329a17 |
---|---|
oai_identifier_str |
oai:scielo:S1677-55382016000200188 |
network_acronym_str |
SBU-1 |
network_name_str |
International Braz J Urol (Online) |
repository_id_str |
|
spelling |
Overactive bladder – 18 years – part IOveractive BladderMuscarinic AntagonistsBeta-adrenergic agonistsBotulinum ToxinSacral neuromodulationUrodynamicsABSTRACT Abstract: Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years.Sociedade Brasileira de Urologia2016-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188International braz j urol v.42 n.2 2016reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-5538.IBJU.2015.0365info:eu-repo/semantics/openAccessTruzzi,Jose CarlosGomes,Cristiano MendesBezerra,Carlos A.Plata,Ivan MauricioCampos,JoseGarrido,Gustavo LuisAlmeida,Fernando G.Averbeck,Marcio AugustoFornari,AlexandreSalazar,AnibalDell'Oro,ArturoCintra,CaioSacomani,Carlos Alberto RicettoTapia,Juan PabloBrambila,EduardoLongo,Emilio MiguelRocha,Flavio TrigoCoutinho,FranciscoFavre,GabrielGarcia,José AntonioCastaño,JuanReyes,MiguelLeyton,Rodrigo EugenioFerreira,Ruiter SilvaDuran,SergioLópez,VandaReges,Ricardoeng2016-05-19T00:00:00Zoai:scielo:S1677-55382016000200188Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2016-05-19T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false |
dc.title.none.fl_str_mv |
Overactive bladder – 18 years – part I |
title |
Overactive bladder – 18 years – part I |
spellingShingle |
Overactive bladder – 18 years – part I Truzzi,Jose Carlos Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics |
title_short |
Overactive bladder – 18 years – part I |
title_full |
Overactive bladder – 18 years – part I |
title_fullStr |
Overactive bladder – 18 years – part I |
title_full_unstemmed |
Overactive bladder – 18 years – part I |
title_sort |
Overactive bladder – 18 years – part I |
author |
Truzzi,Jose Carlos |
author_facet |
Truzzi,Jose Carlos Gomes,Cristiano Mendes Bezerra,Carlos A. Plata,Ivan Mauricio Campos,Jose Garrido,Gustavo Luis Almeida,Fernando G. Averbeck,Marcio Augusto Fornari,Alexandre Salazar,Anibal Dell'Oro,Arturo Cintra,Caio Sacomani,Carlos Alberto Ricetto Tapia,Juan Pablo Brambila,Eduardo Longo,Emilio Miguel Rocha,Flavio Trigo Coutinho,Francisco Favre,Gabriel Garcia,José Antonio Castaño,Juan Reyes,Miguel Leyton,Rodrigo Eugenio Ferreira,Ruiter Silva Duran,Sergio López,Vanda Reges,Ricardo |
author_role |
author |
author2 |
Gomes,Cristiano Mendes Bezerra,Carlos A. Plata,Ivan Mauricio Campos,Jose Garrido,Gustavo Luis Almeida,Fernando G. Averbeck,Marcio Augusto Fornari,Alexandre Salazar,Anibal Dell'Oro,Arturo Cintra,Caio Sacomani,Carlos Alberto Ricetto Tapia,Juan Pablo Brambila,Eduardo Longo,Emilio Miguel Rocha,Flavio Trigo Coutinho,Francisco Favre,Gabriel Garcia,José Antonio Castaño,Juan Reyes,Miguel Leyton,Rodrigo Eugenio Ferreira,Ruiter Silva Duran,Sergio López,Vanda Reges,Ricardo |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Truzzi,Jose Carlos Gomes,Cristiano Mendes Bezerra,Carlos A. Plata,Ivan Mauricio Campos,Jose Garrido,Gustavo Luis Almeida,Fernando G. Averbeck,Marcio Augusto Fornari,Alexandre Salazar,Anibal Dell'Oro,Arturo Cintra,Caio Sacomani,Carlos Alberto Ricetto Tapia,Juan Pablo Brambila,Eduardo Longo,Emilio Miguel Rocha,Flavio Trigo Coutinho,Francisco Favre,Gabriel Garcia,José Antonio Castaño,Juan Reyes,Miguel Leyton,Rodrigo Eugenio Ferreira,Ruiter Silva Duran,Sergio López,Vanda Reges,Ricardo |
dc.subject.por.fl_str_mv |
Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics |
topic |
Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics |
description |
ABSTRACT Abstract: Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1677-5538.IBJU.2015.0365 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
dc.source.none.fl_str_mv |
International braz j urol v.42 n.2 2016 reponame:International Braz J Urol (Online) instname:Sociedade Brasileira de Urologia (SBU) instacron:SBU |
instname_str |
Sociedade Brasileira de Urologia (SBU) |
instacron_str |
SBU |
institution |
SBU |
reponame_str |
International Braz J Urol (Online) |
collection |
International Braz J Urol (Online) |
repository.name.fl_str_mv |
International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU) |
repository.mail.fl_str_mv |
||brazjurol@brazjurol.com.br |
_version_ |
1750318074594066433 |